September 19th 2024
The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical activity in patients with ER-positive, HER2-negative metastatic breast cancer who had previously received endocrine therapy and another CDK4/6 inhibitor.
September 16th 2024
September 15th 2024
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances...
October 10, 2024
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
OS Benefit With Ribociclib Seen Across HR+/HER2- Breast Cancer Settings
August 1st 2019Ribociclib in combination with fulvestrant demonstrated a statistically significant improvement in overall survival in postmenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, according to interim results from the phase III MONALEESA-3 trial.
Read More
Abemaciclib/Fulvestrant Demonstrates OS Benefit in HR+/HER2- Breast Cancer
July 30th 2019The combination of abemaciclib and fulvestrant has demonstrated a statistically significant improvement in overall survival compared with fulvestrant and placebo in women with HR–positive, HER2-negative advanced or metastatic breast cancer who have previously received endocrine therapy, according to updated interim results from the phase III MONARCH 2 trial.
Read More
Pembrolizumab and Chemotherapy Met Primary Endpoint in Phase III TNBC Trial
July 29th 2019The combination of pembrolizumab with chemotherapy demonstrated a benefit in terms of pathological complete response when used as neoadjuvant therapy compared with chemotherapy alone in patients with triple-negative breast cancer, according to interim results of the pivotal phase III KEYNOTE-522 trial.
Read More
Health Canada Approves Extended Adjuvant Neratinib for Early-Stage HR+ Breast Cancer
July 23rd 2019Neratinib has received approval from Health Canada for the treatment of patients with early-stage, hormone receptor–positive, HER2-overexpressed/amplified breast cancer in the extended adjuvant setting. The agent should be given to patients 1 year after completing trastuzumab-based adjuvant therapy.<br />
Read More
Meisel Reviews Systemic Therapies for Breast Cancer With 2 Case Studies
July 17th 2019Jane Lowe Meisel, MD, reviewed systemic therapy options for treating patients with breast cancer with a group of physicians during a <em>Targeted Oncology </em>live case-based peer perspectives discussion. Meisel explained the treatment considerations she makes for treating patients with breast cancer during the dinner event in terms of 2 case studies.
Read More
Encouraging SOLAR-1 Trial Results Lead to Alpelisib Approval
July 8th 2019The SOLAR-1 findings were presented during a satellite symposium at the 2019 European Society for Medical Oncology Breast Cancer Annual Congress in Berlin, Germany. The trial demonstrated the role of <em>PIK3CA </em>as a predictive marker for alpelisib’s clinical efficacy, said Peter A. Fasching, MD, associate professor of gynecology and obstetrics at Friedrich-Alexander University of Erlangen-Nuremberg in Germany, during the symposium.
Read More
Tolerability Improves With Prophylactic Strategies for Adjuvant Neratinib in HER2+ Breast Cancer
July 8th 2019Preventive strategies for severe diarrhea associated with adjuvant treatment with neratinib improved tolerability for the agent when patients received budesonide or colestipol-with-loperamide prophylaxis, according to findings from the CONTROL study.
Read More
With Biomarker Expansion, Combinations and Personalized Medicine Continue to Rise
July 5th 2019Biomarker expansion has enjoyed a boom since 2006, with patient incidence of positive biomarkers reaching up to 50% in non–small cell lung cancer and melanoma and 25% in acute myeloid leukemia and myelodysplastic syndromes, according to the <em>Global Oncology Trends 2018</em> report.
Read More
Patients With MBC Have Reduced Toxicity Burden With Dual HER2-Targeted Therapy in the Front Line
July 4th 2019Patients with HER2-positive metastatic breast cancer receiving frontline HER2-targeted therapy with pertuzumab and trastuzumab followed by T-DM1 in the second-line setting may be able to forgo chemotherapy without increasing the risk of early death, according to results from the phase II PERNETTA trial.
Read More